LSP GR1
Alternative Names: LSP-GR1Latest Information Update: 28 Feb 2023
Price :
$50 *
At a glance
- Originator LifeSplice
- Class Antiepileptic drugs; Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Epilepsy
- No development reported Amyotrophic lateral sclerosis
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
- 05 Jul 2021 LSP GR1 is available for licensing as of 05 Jul 2021. http://lifesplicepharma.com/investors-partners/
- 05 Jul 2021 Preclinical trials in Epilepsy in USA (unspecified route) before July 2021 (LifeSplice pipeline, July 2021)